Núria López-Bigas

Núria López-Bigas

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Núria López-Bigas

Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2020 in Nature
Verified
Journal Article
Open access
PDF file
LALudmil B. Alexandrov
Ludmil B. Alexandrov
JKJaegil Kim
Jaegil Kim
NHNicholas J. Haradhvala
Nicholas J. Haradhvala
MHMi Ni Huang
Mi Ni Huang
ANAlvin Wei Tian Ng
Alvin Wei Tian Ng
MSMichael R. Stratton
Michael R. Stratton
Somatic mutations in cancer genomes are caused by multiple mutational processes, each of which generates a characteristic mutational signature1. Here, as part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium2 of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA), we characterized mutational signatures using 84,729,690 somatic mutations from 4,645 whole-genome and 19,184 exome sequences that encompass most types of cancer. We identified 49 single-base-substitution, 11 doublet-base-substitution, 4 clustered-base-substitution and 17 small insertion-and-deletion signatures. The substantial size of our dataset, compared with previous analyses3–15, enabled the discovery of new signatures, the separation of overlapping signatures and the decomposition of signatures into components that may represent associated—but distinct—DNA damage, repair and/or replication mechanisms. By estimating the contribution of each signature to the mutational catalogues of individual cancer genomes, we revealed associations of signatures to exogenous or endogenous exposures, as well as to defective DNA-maintenance processes. However, many signatures are of unknown cause. This analysis provides a systematic perspective on the repertoire of mutational processes that contribute to the development of human cancer.

1 July 2016 in Cell
Verified
Journal Article
Open access
Francesco IorioFrancesco Iorio
Francesco Iorio
TKTheo A. Knijnenburg
Theo A. Knijnenburg
DVDaniel J. Vis
Daniel J. Vis
GBGraham R. Bignell
Graham R. Bignell
MMMichael P. Menden
Michael P. Menden
MGMathew J. Garnett
Mathew J. Garnett
Systematic studies of cancer genomes have provided unprecedented insights into the molecular nature of cancer. Using this information to guide the development and application of therapies in the clinic is challenging. Here, we report how cancer-driven alterations identified in 11,289 tumors from 29 tissues (integrating somatic mutations, copy number alterations, DNA methylation, and gene expression) can be mapped onto 1,001 molecularly annotated human cancer cell lines and correlated with sensitivity to 265 drugs. We find that cell lines faithfully recapitulate oncogenic alterations identified in tumors, find that many of these associate with drug sensitivity/resistance, and highlight the importance of tissue lineage in mediating drug response. Logic-based modeling uncovers combinations of alterations that sensitize to drugs, while machine learning demonstrates the relative importance of different data types in predicting drug response. Our analysis and datasets are rich resources to link genotypes with cellular phenotypes and to identify therapeutic options for selected cancer sub-populations.

1 April 2018 in Cell
Verified
Journal Article
Open access
MBMatthew H. Bailey
Matthew H. Bailey
CTCollin Tokheim
Collin Tokheim
EPEduard Porta-Pardo
Eduard Porta-Pardo
SSSohini Sengupta
Sohini Sengupta
DBDenis Bertrand
Denis Bertrand
RKRachel Karchin
Rachel Karchin
Identifying molecular cancer drivers is critical for precision oncology. Multiple advanced algorithms to identify drivers now exist, but systematic attempts to combine and optimize them on large datasets are few. We report a PanCancer and PanSoftware analysis spanning 9,423 tumor exomes (comprising all 33 of The Cancer Genome Atlas projects) and using 26 computational tools to catalog driver genes and mutations. We identify 299 driver genes with implications regarding their anatomical sites and cancer/cell types. Sequence- and structure-based analyses identified >3,400 putative missense driver mutations supported by multiple lines of evidence. Experimental validation confirmed 60%-85% of predicted mutations as likely drivers. We found that >300 MSI tumors are associated with high PD-1/PD-L1, and 57% of tumors analyzed harbor putative clinically actionable events. Our study represents the most comprehensive discovery of cancer genes and mutations to date and will serve as a blueprint for future biological and clinical endeavors.

1 August 2014 in Cell
Verified
Journal Article
Closed access
KHKatherine A Hoadley
Katherine A Hoadley
CYChristina Yau
Christina Yau
DWDenise M. Wolf
Denise M. Wolf
ACAndrew D. Cherniack
Andrew D. Cherniack
DTDavid Tamborero
David Tamborero
JSJoshua M. Stuart
Joshua M. Stuart

3 May 2017 in Nature
Verified
Journal Article
Closed access
Nicholas K. HaywardNicholas K. Hayward
Nicholas K. Hayward
JWJames Wilmott
James Wilmott
Nic WaddellNic Waddell
Nic Waddell
PJPeter A Johansson
Peter A Johansson
MFMatthew Field
Matthew Field
GMGraham J Mann
Graham J Mann

10 August 2020 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
FMFrancisco Martínez-Jiménez
Francisco Martínez-Jiménez
FMFerran Muiños
Ferran Muiños
ISInés Sentís
Inés Sentís
JDJordi Deu-Pons
Jordi Deu-Pons
IRIker Reyes-Salazar
Iker Reyes-Salazar
NLNuria Lopez-Bigas
Nuria Lopez-Bigas